MA49059A - Traitement des cancers positifs à her2 - Google Patents

Traitement des cancers positifs à her2

Info

Publication number
MA49059A
MA49059A MA049059A MA49059A MA49059A MA 49059 A MA49059 A MA 49059A MA 049059 A MA049059 A MA 049059A MA 49059 A MA49059 A MA 49059A MA 49059 A MA49059 A MA 49059A
Authority
MA
Morocco
Prior art keywords
treatment
positive her2
cancers
her2 cancers
positive
Prior art date
Application number
MA049059A
Other languages
English (en)
Inventor
Scott Peterson
Luke Walker
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MA49059A publication Critical patent/MA49059A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049059A 2017-04-28 2018-04-27 Traitement des cancers positifs à her2 MA49059A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762491872P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
MA49059A true MA49059A (fr) 2021-03-24

Family

ID=62165692

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049059A MA49059A (fr) 2017-04-28 2018-04-27 Traitement des cancers positifs à her2

Country Status (13)

Country Link
US (3) US11207324B2 (fr)
EP (1) EP3615067A1 (fr)
JP (2) JP7328151B2 (fr)
KR (1) KR20200014298A (fr)
CN (1) CN111032082A (fr)
AU (2) AU2018258663B2 (fr)
BR (1) BR112019022280A2 (fr)
CA (1) CA3060407A1 (fr)
EA (1) EA201992573A1 (fr)
MA (1) MA49059A (fr)
SG (1) SG11201909676WA (fr)
WO (1) WO2018201016A1 (fr)
ZA (1) ZA201907225B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032082A (zh) 2017-04-28 2020-04-17 西雅图基因公司 Her2阳性癌症的治疗
TW202042820A (zh) * 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
JP7438496B2 (ja) * 2019-06-11 2024-02-27 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストの使用
CN114746094A (zh) * 2019-10-21 2022-07-12 思进公司 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法
WO2021243123A1 (fr) * 2020-05-29 2021-12-02 Seagen Inc. Procédés de traitement du cancer positif her2 au moyen de tucatinib en combinaison avec du trastuzumab et une chimiothérapie à base d'oxaliplatine
AU2021349384A1 (en) * 2020-09-28 2023-05-25 Seagen Inc. Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images
WO2024183622A1 (fr) * 2023-03-03 2024-09-12 盛禾(中国)生物制药有限公司 Utilisation d'un anticorps anti-her2 dans la préparation d'un médicament pour le traitement du cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
CA2129514A1 (fr) 1992-03-12 1993-09-16 M. Amin Khan Acth a liberation controlee, contenant des microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US7452895B2 (en) 2003-08-14 2008-11-18 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR20070030240A (ko) 2004-06-03 2007-03-15 스미스클라인 비이참 (코르크) 리미티드 암 치료 방법
ZA200804498B (en) 2005-11-15 2009-07-29 Array Biopharma Inc N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
CA2700673A1 (fr) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies pour traiter le cancer en utilisant des combinaisons d'inhibiteurs de cox-2 et des anticorps anti-her2(erbb2) ou des combinaisons d'inhibiteurs de cox-2 et des inhibiteurs du recepteur her2(erbb2) de la tyrosine kinase
US8663643B2 (en) 2008-03-18 2014-03-04 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP2896632B1 (fr) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Matériau et procédés de traitement ou de prévention de maladies associées à des HER-3
JP6468838B2 (ja) * 2011-05-19 2019-02-13 ラボラトリー コーポレイション オブ アメリカ ホールディングス 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
WO2013056183A1 (fr) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphes de arry-380, inhibiteur sélectif de herb2 et compositions pharmaceutiques les contenant
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
NZ724544A (en) 2012-03-23 2018-05-25 Array Biopharma Inc Treatment of brain cancer
WO2016201370A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
CN109952306A (zh) * 2016-04-19 2019-06-28 加利福尼亚大学董事会 ErbB抑制剂及其用途
CN111032082A (zh) 2017-04-28 2020-04-17 西雅图基因公司 Her2阳性癌症的治疗
US20210239702A1 (en) 2018-06-14 2021-08-05 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
TW202042820A (zh) 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
CN114746094A (zh) 2019-10-21 2022-07-12 思进公司 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法
WO2021097220A1 (fr) 2019-11-15 2021-05-20 Seagen Inc. Méthodes de traitement du cancer du sein her2 positif avec du tucatinib en combinaison avec un conjugué médicament-anticorps anti-her2
IL296227A (en) 2020-03-11 2022-11-01 Seagen Inc Methods for treating her2 mutant cancer with toctinib

Also Published As

Publication number Publication date
KR20200014298A (ko) 2020-02-10
SG11201909676WA (en) 2019-11-28
JP2020517696A (ja) 2020-06-18
ZA201907225B (en) 2023-11-29
EP3615067A1 (fr) 2020-03-04
EA201992573A1 (ru) 2020-04-06
US12048698B2 (en) 2024-07-30
US11666572B2 (en) 2023-06-06
BR112019022280A2 (pt) 2020-05-19
JP7328151B2 (ja) 2023-08-16
AU2018258663A1 (en) 2019-11-14
CN111032082A (zh) 2020-04-17
JP2023145689A (ja) 2023-10-11
AU2022241509A1 (en) 2022-10-27
US20220168303A1 (en) 2022-06-02
US20230390290A1 (en) 2023-12-07
WO2018201016A1 (fr) 2018-11-01
US11207324B2 (en) 2021-12-28
CA3060407A1 (fr) 2018-11-01
AU2018258663B2 (en) 2022-08-04
US20200188401A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MA49059A (fr) Traitement des cancers positifs à her2
MA49144A (fr) Polythérapies pour le traitement du cancer
MA50056A (fr) Procédés de traitement de tumeur
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA41449A (fr) Polythérapies pour le traitement de cancers
MA43190A (fr) Traitement de la dyslipidémie mixte
MA47408A (fr) Traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
DK3458052T3 (da) Kombinationsbehandling af cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
MA46361A (fr) Traitement du cancer de la prostate
DK3458610T3 (da) Terapeutisk behandling af brystcancer baseret på c-MAF-status
DK3589661T3 (da) Adjuvansbehandling af HER2-positiv brystcancer
MA52627A (fr) Traitement du cancer
MA52218A (fr) Traitement de cancers associés à trk
IL266324A (en) Treatment of her2-positive breast cancer
DK3525774T3 (da) Lasofoxifen behandling af er+ brystcancer
IL263835A (en) Exosome-guided treatment of cancer
MA42930A (fr) Traitement de maladies neurodégénératives
GB201618424D0 (en) Treatment of antibody mediated disease
DK3576740T3 (da) Cancerbehandling